Amylin Pharmaceuticals

Amylin Pharmaceuticals, Inc.
TypeSubsidiary
Nasdaq: AMLN
IndustryBiotechnology
Founded1987 (1987)
Defunct2014 (2014)
FateAcquired by Bristol-Myers Squibb and AstraZeneca
HeadquartersSan Diego, California, United States
Key peopleDaniel M. Bradbury
ProductsSymlin (pramlintide)
Byetta (exenatide)
Bydureon (exenatide long-acting release)
RevenueDecreaseUS$651 million (2011)
Decrease US$−543 million (2011)
Total assetsIncrease US$1.87 billion (2011)
Total equityDecrease US$−139 million (2011)
Number of employees
1,300 (2011)
SubsidiariesAmylin Ohio LLC

Amylin Pharmaceuticals, Inc. was a biopharmaceutical company founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended release).